Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24928311
DOI
10.1016/j.ijantimicag.2014.04.007
PII: S0924-8579(14)00131-9
Knihovny.cz E-resources
- Keywords
- Economics, Intravenous line days, Intravenous-to-oral antibiotic switch, Length of stay, Linezolid, Vancomycin,
- MeSH
- Acetamides economics therapeutic use MeSH
- Anti-Bacterial Agents economics therapeutic use MeSH
- Administration, Oral MeSH
- Length of Stay economics statistics & numerical data MeSH
- Adult MeSH
- Hospitalization economics statistics & numerical data MeSH
- Soft Tissue Infections drug therapy economics microbiology pathology MeSH
- Injections, Intravenous MeSH
- Middle Aged MeSH
- Humans MeSH
- Linezolid MeSH
- Methicillin-Resistant Staphylococcus aureus drug effects growth & development MeSH
- Oxazolidinones economics therapeutic use MeSH
- Patient Discharge MeSH
- Retrospective Studies MeSH
- Drug Administration Schedule MeSH
- Aged MeSH
- Practice Guidelines as Topic MeSH
- Staphylococcal Skin Infections drug therapy economics microbiology pathology MeSH
- Vancomycin economics therapeutic use MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Europe MeSH
- Names of Substances
- Acetamides MeSH
- Anti-Bacterial Agents MeSH
- Linezolid MeSH
- Oxazolidinones MeSH
- Vancomycin MeSH
This retrospective observational medical chart review aimed to describe country-specific variations across Europe in real-world meticillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft-tissue infection (cSSTI) treatment patterns, antibiotic stewardship activity, and potential opportunities for early switch (ES) from intravenous (i.v.) to oral formulations and early discharge (ED) from hospital using standardised data collection and criteria and economic implications of these opportunities. Patients were randomly sampled from 12 countries (Austria, Czech Republic, France, Germany, Greece, Ireland, Italy, Poland, Portugal, Slovakia, Spain and the UK), aged ≥18 years, with documented MRSA cSSTI, hospitalised between 1 July 2010 and 30 June 2011, discharged alive by 31 July 2011. Of 1502 patients, 1468 received MRSA-targeted therapy. Intravenous-to-oral switch rates ranged from 2.0% to 20.2%, i.v. length of therapy from 10.1 to 18.6 days and hospital length of stay (LoS) from 15.2 to 25.0 days across Europe. Of 341 sites, 82.9% had antibiotic steering committees, 23.7% had i.v.-to-oral switch antibiotic protocols and 12.9% had ED protocols for MRSA cSSTI. ES and ED eligibility ranged from 12.0% (Slovakia) to 56.3% (Greece) and from 10% (Slovakia) to 48.2% (Portugal), respectively. Potential cost savings per ED-eligible patient ranged from €414 (Slovakia) to €2703 (France). MRSA cSSTI treatment patterns varied widely across countries, but further reductions in i.v. therapy, hospital LoS and associated costs could be realised. These data provide insight into clinical practice patterns across diverse European healthcare systems and identify potential opportunities for local clinicians and policy-makers to improve clinical care and cost-effectiveness of this therapeutic area.
Imperial College Healthcare NHS Trust London UK
Klinikum Peine and Medical University Hannover Peine Germany
Medical Data Analytics Parsippany NJ USA
Ninewells Hospital and Medical School Dundee UK
Pfizer Inc Collegeville PA USA
References provided by Crossref.org
